https://scholars.lib.ntu.edu.tw/handle/123456789/557937
標題: | Molecular-targeted therapy for chemotherapy-refractory gastric cancer: A case report and literature review | 作者: | HUNG-YANG KUO KUN-HUEI YEH |
公開日期: | 2014 | 出版社: | International Institute of Anticancer Research | 卷: | 34 | 期: | 7 | 起(迄)頁: | 3695-3699 | 來源出版物: | Anticancer Research | 摘要: | The prognosis of advanced gastric cancer (AGC) remains poor despite therapeutic advances in recent decades. Several recent positive phase III trials established the efficacy of second-line chemotherapy for metastatic gastric cancer in prolonging overall survival. However, malnutrition and poor performance of AGC in late stages usually preclude such patients from intensive treatment. Many targeted-therapies failed to show a significant survival benefit in AGC, but have regained attention after the positive result of ramucirumab was announced last year. Among all targeted agents, only trastuzumab, a monoclonal antibody against Human epidermal growth factor receptor-2 (HER2) protein, has been proven as having survival benefit by addition to first-line chemotherapy. Herein we reported a patient who benefited from adding trastuzumab to the same second-line combination chemotherapy (paclitaxel, 5-fluorouracil, and leucovorin) upon progression of bulky liver metastases. At least five months of progression-free survival were achieved without any additional toxicity. We also reviewed literature of molecularly-targeted therapy for chemotherapy-refractory gastric cancer, including several large phase III trials (REGARD, GRANITE-1, EXPAND, and REAL-3) published in 2013-2014. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84906319290&partnerID=40&md5=66c5e6edfeedcbff45f3123bf9c5ecf4 https://scholars.lib.ntu.edu.tw/handle/123456789/557937 |
ISSN: | 0250-7005 | SDG/關鍵字: | cisplatin; epidermal growth factor receptor 2; everolimus; fluorouracil; folinic acid; paclitaxel; ramucirumab; trastuzumab; antineoplastic agent; monoclonal antibody; trastuzumab; abdominal distension; adult; Article; cancer chemotherapy; cancer staging; cancer survival; case report; combination chemotherapy; computer assisted tomography; deterioration; disease course; disease duration; distant metastasis; drug megadose; epigastric pain; gastrointestinal endoscopy; gastrointestinal hemorrhage; human; liver metastasis; low drug dose; lymphadenopathy; male; molecularly targeted therapy; multiple cycle treatment; multiple organ failure; phase 3 clinical trial (topic); progression free survival; Roux Y anastomosis; salvage therapy; stomach cancer; total stomach resection; treatment response; tumor volume; adenocarcinoma; article; chemotherapy; disease free survival; drug resistance; middle aged; molecularly targeted therapy; pathology; ramucirimab; randomized controlled trial (topic); refractory; stomach cancer; stomach tumor; targeted therapy; chemotherapy; Gastric cancer; ramucirimab; refractory; targeted therapy; trastuzumab; Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Randomized Controlled Trials as Topic; Stomach Neoplasms |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。